They're dirt cheap compared to their peers.
News & Analysis: Biogen
Biogen's Alzheimer's disease drug, aducanumab, got positive news from the FDA last week. If the drug is approved, what does that mean for other companies with prospective Alzheimer's drug candidates?
This biotech titan should be a top player on the merger and acquisition scene next year.
The odds appear to be heavily against this Berkshire investment paying off.
The biotech's high-profile Alzheimer's disease drug candidate appears to be headed for a rejection.
The committee of outside experts saw right through the FDA's cheerleading.
The day is finally upon us.
Find out why Biogen, Uber, and Lyft were higher on the day.
Their long-term prospects are what really matter.
The company has struggled with drug pipeline progress, but it is still confident in its ability to provide long-term returns.